Does Rallies track congressional trades in AZN?

Yes. Rallies tracks politician and congressional stock disclosures for AZN, including reported purchases, sales, dates, owners, and trade amounts when available.

Is AZN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for AZN. It does not provide personalized investment advice.

AZN (AstraZeneca PLC) Stock Analysis - Politician Trades

AstraZeneca PLC (AZN) is a publicly traded Healthcare sector company. As of May 20, 2026, AZN trades at $187.48 with a market cap of $285.23B and a P/E ratio of 0.00. AZN moved +1.54% today. Year to date, AZN is +101.64%; over the trailing twelve months it is +164.94%. Its 52-week range spans $61.24 to $212.71. Analyst consensus is strong buy with an average price target of $214.28. Rallies surfaces AZN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded AZN stock?

Recent politician trading activity in AZN includes disclosures from Julia Letlow, Gilbert Cisneros, Lisa McClain, Lisa McClain, and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

AZN Key Metrics

Key financial metrics for AZN
Metric	Value
Price	$187.48
Market Cap	$285.23B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	1.59%
52-Week High	$212.71
52-Week Low	$61.24
Volume	1.42M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Congressional Trades in AZN

Julia Letlow purchase AZN on Dec 8, 2025 (amount: $15.00K).
Gilbert Cisneros purchase AZN on Nov 19, 2025 (amount: $15.00K).
Lisa McClain sale AZN on Oct 31, 2025 (amount: $15.00K) for Spouse.
Lisa McClain purchase AZN on Oct 30, 2025 (amount: $15.00K) for Spouse.
Gilbert Cisneros purchase AZN on Oct 21, 2025 (amount: $15.00K).

Latest AZN News

AstraZeneca Gains FDA Approval for Baxfendy, Targets $5 Billion Hypertension Market — May 18, 2026
Primecap Cuts AstraZeneca Stake Representing 2.57% Portfolio Weight — May 11, 2026
FDA Panel Rejects AstraZeneca’s Camizestrant, Shares Drop 2% — May 1, 2026
Citi Raises AstraZeneca's 2026 EPS to $10.30, Sees Five Key Trials — Apr 30, 2026
AstraZeneca Pays $25M to License PTX-299 EGFR Degrader, Eyes $500M Milestones — Apr 29, 2026

AZN Analyst Consensus

15 analysts cover AZN: 0 strong buy, 13 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $214.28.

Common questions about AZN

Which politicians traded AZN stock?: Recent politician trading activity in AZN includes disclosures from Julia Letlow, Gilbert Cisneros, Lisa McClain, Lisa McClain, and Gilbert Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in AZN?: Yes. Rallies tracks politician and congressional stock disclosures for AZN, including reported purchases, sales, dates, owners, and trade amounts when available.
Is AZN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for AZN. It does not provide personalized investment advice.